R J Bryant1, N A Cross, C L Eaton, F C Hamdy, V T Cunliffe. 1. MRC Centre Development for Developmental and Biomedical Genetics, University of Sheffield, Firth Court, Western Bank, Sheffield, United Kingdom.
Abstract
BACKGROUND: The transcriptional repressor EZH2 is implicated in control of cell proliferation in embryonic, immortalized and transformed cells. EZH2 expression in prostate cancer correlates with progression to hormone-refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype. METHODS: Using siRNA knockdown, we investigated the role of EZH2 in maintenance of prostate cancer cell proliferation and invasiveness. Using LNCaP cells with inducible EZH2 overexpression, we investigated whether EZH2 upregulation promotes an aggressive phenotype. RESULTS: Knockdown of endogenous EZH2 reduced proliferation of androgen-responsive and androgen-independent prostate cancer cells. EZH2 knockdown also inhibited prostate cancer cell invasion. However, overexpression of EZH2 in androgen-responsive cancer cells did not appreciably affect either proliferation or invasiveness. CONCLUSIONS: EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis.
BACKGROUND: The transcriptional repressor EZH2 is implicated in control of cell proliferation in embryonic, immortalized and transformed cells. EZH2 expression in prostate cancer correlates with progression to hormone-refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype. METHODS: Using siRNA knockdown, we investigated the role of EZH2 in maintenance of prostate cancer cell proliferation and invasiveness. Using LNCaP cells with inducible EZH2 overexpression, we investigated whether EZH2 upregulation promotes an aggressive phenotype. RESULTS: Knockdown of endogenous EZH2 reduced proliferation of androgen-responsive and androgen-independent prostate cancer cells. EZH2 knockdown also inhibited prostate cancer cell invasion. However, overexpression of EZH2 in androgen-responsive cancer cells did not appreciably affect either proliferation or invasiveness. CONCLUSIONS: EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis.
Authors: Q Cao; J Yu; S M Dhanasekaran; J H Kim; R-S Mani; S A Tomlins; R Mehra; B Laxman; X Cao; J Yu; C G Kleer; S Varambally; A M Chinnaiyan Journal: Oncogene Date: 2008-09-22 Impact factor: 9.867
Authors: Sharmila A Bapat; Victor Jin; Nicholas Berry; Curt Balch; Neeti Sharma; Nawneet Kurrey; Shu Zhang; Fang Fang; Xun Lan; Meng Li; Brian Kennedy; Robert M Bigsby; Tim H M Huang; Kenneth P Nephew Journal: Epigenetics Date: 2010-11-01 Impact factor: 4.528
Authors: Paul Cao; Zhiyong Deng; Meimei Wan; Weiwei Huang; Scott D Cramer; Jianfeng Xu; Ming Lei; Guangchao Sui Journal: Mol Cancer Date: 2010-05-17 Impact factor: 27.401
Authors: Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi Journal: Curr Cancer Drug Targets Date: 2013-06 Impact factor: 3.428